• Twi Biotechnology Inc., of Taipei, Taiwan, said it completed enrollment in a Phase II trial of AC-201 for gout flare prophylaxis during urate-lowering therapy (ULT). The randomized study includes patients with acute arthritis of primary gout and elevated serum uric acid.